Canadian Journal of Gastroenterology and Hepatology

Canadian Journal of Gastroenterology and Hepatology / 2001 / Article

Review | Open Access

Volume 15 |Article ID 403102 | https://doi.org/10.1155/2001/403102

Roger B Cohen, Karen A Dittrich, "Anti-TNF Therapy and Malignancy – A Critical Review", Canadian Journal of Gastroenterology and Hepatology, vol. 15, Article ID 403102, 9 pages, 2001. https://doi.org/10.1155/2001/403102

Anti-TNF Therapy and Malignancy – A Critical Review

Received13 Jul 2000
Accepted03 Apr 2001

Abstract

The roles of tumour necrosis factor (TNF) and anti-TNF therapy in malignancy are reviewed, including an overview of baseline risk factors for malignancy in inflammatory diseases and the incidences of malignancies observed in clinical trials of an anti-TNF-a therapy, infliximab. The preclinical data and early clinical experience presented for infliximab do not provide evidence for a causal relationship between TNF-a antagonism and the development of lymphoid or nonlymphoid cancers.

Copyright © 2001 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views157
Downloads336
Citations

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.